MARKET

INAB

INAB

In8Bio, Inc.
NASDAQ
2.140
+0.040
+1.90%
Opening 10:08 07/08 EDT
OPEN
2.130
PREV CLOSE
2.100
HIGH
2.156
LOW
2.126
VOLUME
9.88K
TURNOVER
--
52 WEEK HIGH
27.30
52 WEEK LOW
2.050
MARKET CAP
7.37M
P/E (TTM)
-0.1464
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at INAB last week (0630-0704)?
Weekly Report · 1d ago
I-Mab Publishes First-in-Human Data For Givastomig Monotherapy In 'Clinical Cancer Research', Showing Up To 18% Response Rate In Heavily Pretreated Gastric Cancer Patients; Safety And Efficacy Support Ongoing 1L Combination Trials With Nivolumab And Chemotherapy
Benzinga · 06/30 20:02
IN8bio Regains Nasdaq Compliance with Bid Price Rule
TipRanks · 06/30 18:48
Weekly Report: what happened at INAB last week (0623-0627)?
Weekly Report · 06/30 09:35
Weekly Report: what happened at INAB last week (0616-0620)?
Weekly Report · 06/23 09:33
Weekly Report: what happened at INAB last week (0609-0613)?
Weekly Report · 06/16 09:35
IN8bio recognizes 4-years in remission for patient treated with INB-200
TipRanks · 06/09 11:21
IN8bio Announces Patient 009 In Phase 1 Trial Of INB-200 For Newly-Diagnosed GBM Reaches Significant Clinical Milestone
Benzinga · 06/09 11:06
More
About INAB
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.

Webull offers IN8bio Inc stock information, including NASDAQ: INAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INAB stock methods without spending real money on the virtual paper trading platform.